© 2025 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Latest Conference Articles
Rheumatologists' Biosimilar Awareness Is Growing, But Their Confidence Has Room to Improve
Kelly Davio
November 11 2019
American College of Rheumatology Annual Meeting
Over the past few years, awareness of biosimilars has been increasing; however, research presented at the American College of Rheumatology’s 2019 meeting, being held in Atlanta, Georgia, shows that while US rheumatologists hold growing awareness of biosimilars, hesitancy remains around such issues as switching stable patients and the extrapolation of indications.
At ACR, New Data for Amgen's Proposed Infliximab and Rituximab Biosimilars in RA
Kelly Davio
November 11 2019
American College of Rheumatology Annual Meeting
On Sunday, during the American College of Rheumatology (ACR)’s 2019 meeting, being held in Atlanta, Georgia, researchers reported on the safety and efficacy of the proposed infliximab biosimilar ABP 710 in a phase 3 study of patients with rheumatoid arthritis (RA). Researchers also reported on a phase 1 and 3 study of the proposed rituximab biosimilar, ABP 798, in patients with RA.
Applying Biosimilar Savings in Markets Around the World
Kelly Davio
November 8 2019
The great promise of biosimilars is their ability to provide high-quality treatment at a reduced cost, thereby producing cost savings that can be reapplied. But how are healthcare systems around the globe utilizing those cost savings? During the International Society for Pharmacoeconomics and Outcomes Research 2019 meeting, held this week in Copenhagen, Denmark, several teams of researchers reported on how biosimilars are impacting international markets, and how they could provide headroom for new, expensive treatments.
Studies Give a Window Into the Evolving French Biosimilars Market
Kelly Davio
November 6 2019
France has experimented with financial incentives to reward the prescribing of biosimilars. These incentive structures include shared savings for centers that acquire medicines at lower costs, as well as biosimilar prescribing targets.
Perceptions and Policies Still Holding Back Biosimilars in Europe
Kelly Davio
November 5 2019
During the International Society for Pharmacoeconomics and Outcomes Research 2019 meeting being held in Copenhagen, Denmark, 3 teams of researchers presented findings that show that, despite the fact that Europe’s biosimilars market is far more mature than that of the United States, the region still sees setbacks from stakeholder perceptions of biosimilars and from policies that do not adequately incentivize biosimilar use.
Amgen's Anticancer Biosimilars Could Provide Substantial Hospital Budget Savings to Italian System
Kelly Davio
November 4 2019
The International Society for Pharmacoeconomics and Outcomes Research is holding its Europe 2019 meeting this week in Copenhagen, Denmark, and the savings that biosimilars can afford European healthcare systems are a hot topic at this year’s event. Two studies presented on Monday explored how Amgen’s biosimilar bevacizumab (Mvasi) and biosimilar trastuzumab (Kanjinti) could produce significant cost savings for hospitals in the Italian healthcare system.
Arrow Declarations Are an Emerging Feature in the Biosimilar Patent Landscape
Kelly Davio
September 27 2019
In the US context, legal issues surrounding patents are often cited as one of the main hurdles to biosimilars. Despite the fact that patents on innovator drugs are often fewer in Europe, the patent landscape in the European Union remains complex and continues to evolve. During the SMi 10th Annual Biosimilars Conference, Gregory Bacon, DPhil, GDipIPLaw, partner at Bristows LLP, gave attendees a closer look at one emerging feature of the EU patent landscape that is of particular concern to biosimilar developers: the Arrow declaration.
Biosimilar Developers Have the Chance to Innovate With Device Design, Novartis Leader Says
Kelly Davio
September 26 2019
Innovation is not always the first term that comes to mind with respect to biosimilars; after all, having no clinically relevant differences between products is at the heart of biosimilarity. However, as Sebastian Maag, device project leader for Novartis–Sandoz GmbH, told attendees during the second day of the SMi 10th Annual Biosimilars Conference, biosimilar developers have the opportunity to introduce innovations with the design of their devices for drug delivery.
